Kornimate/medical-research-clean huggingface dataset:
ex vivo drug sensitivity testing and mutation profiling

Conditions: Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Large Cell Lymphoma; Refractory Childhood Acute Lymphoblastic Leukemia; Refractory Childhood Hodgkin Lymphoma; Refractory Childhood Malignant Germ Cell Neoplasm; Recurrent Childhood Brain Tumor; Recurrent Childhood Brainstem Glioma; Recurrent Childhood Rhabdomyosarcoma; Recurrent Childhood Soft Tissue Sarcoma; Recurrent Childhood Ependymoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Gliosarcoma; Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive

Summary: this study is a prospective, non-randomized feasibility study. freshly isolated tumor cells from patients will be screened using state-of-the-art viability assay designed for ex vivo high-throughput drug sensitivity testing (dst). in addition, genetic information will be obtained from cancer and normal (germline) tissue and correlated with drug response. this study will provide the platform for informing treating physician about individualized treatment options. the main outcome of this study will be the proportions of the patients whose treatment was guided by the personalized medicine approach.

primary objective: the primary objective of the study is to determine feasibility of providing pediatric cancer patients with access to personalized treatment options and clinical management recommendations based on ex vivo drug sensitivity testing (dst) and genomic profiling. secondary objective: the secondary objective of the study is to compare individual outcomes (response and disease-free survival) in patients with pediatric cancers treated with dst-guided therapy as compared to non-dst guided (conventional) therapy. exploratory objective: to explore associations between genetic abnormalities in malignancies and ex vivo drug response.

Eligibility criteria:
inclusion criteria: * patients aged 21 years or younger at the time of enrollment on this study of any gender, race or ethnicity. * subjects with suspected or confirmed diagnosis of recurrent or refractory cancer * subjects who are scheduled for or have recently had biopsy or tumor excised (solid tumors) or bone marrow aspirate (blood cancers) * subjects willing to have a blood draw or buccal swab done for the purposes of genetic testing * subjects or their parents or legal guardians willing to sign informed consent * subjects aged 7 to 17 willing to sign assent exclusion criteria: * subjects who do not have malignant tissue available and accessible * the amount of excised malignant tissue is not sufficient for the ex vivo drug testing and/or genetic profiling. * patients with newly diagnosed tumors and tumors that have high (\>90%) cure rate with safe standard therapy.

Keywords: ex vivo drug sensitivity assay genomic profiling
assessing depression in a geriatric cancer population

Conditions: Breast Cancer; Prostate Cancer

Summary: the goal of this study is to learn more about how we measure depression in elderly cancer patients (patients aged 70 and older). depression is one of the most common causes of emotional distress in the elderly and continues to be under-recognized. this is a problem because depression can have a negative impact on quality of life. the symptoms of depression are linked to poor health outcomes and higher costs of health care. in fact, depression is one of the top five concerns facing the elderly today.

we have a few questionnaires that have been used to measure depression, but we do not know how these measures work with people with cancer. this study will help us answer this question. to complete this study, we need people who may or may not be feeling down or depressed. if you choose to take part, you will be asked to do the following: 1. fill out questionnaires that ask about: * your age, eduction, race, and income * your mood in all, these questionnaires will take about 10 minutes to complete. 2. answer questions about your mood. this will also take about 10 minutes to complete.

Eligibility criteria:
inclusion criteria: 1. age 70 and older 2. diagnosis of early or late stage prostate cancer, or diagnosis of early or late stage breast cancer 3. actively engaged in one of the following cancer treatments: chemotherapy, radiation therapy, hormone therapy 4. able to provide informed consent 5. ability to converse, write and read english exclusion criteria: 1.major psychopathology or cognitive impairment likely in the judgment of the research staff to interfere with the participation or completion of the protocol.

Keywords: breast cancer prostate cancer
new position for endotracheal intubation of obese patients

Conditions: Obesity; Anesthesia

Summary: the aim of this work is to investigate the feasibility of using the modified a ramped position for mask ventilation and endotracheal intubation of obese patients in comparison to the traditional ramped position

adequate conditions for endotracheal intubation and mask ventilation require appropriate positioning of head and neck. the sniffing position had been described as the most appropriate head position for endotracheal intubation. sniffing position is achieved through two main components: flexion of the neck by 35° (achieved by head elevation) and extension of the head by 15° 2 to have the sternum at the same level of external auditory meatus 34. sniffing position has the advantage of alignment of the three axes: oral, pharyngeal, and laryngeal axes for reaching the optimal laryngeal visualization. in obese patients, it is recommended to put the patient in the ramped position (back-up position with the tragus of the ear is at the level of the suprasternal notch) in addition to the sniffing head-and-neck position. in addition to difficult laryngeal visualization, another problem commonly confronts anesthetists during intubation of obese such as: 1- impedance to complete mouth opening due to fatty face and neck. 2- impedance of laryngoscopy by large breasts in females. this problem commonly hinders the intubation process and might lead to serious hypoxia. most of the positions described in literature were concerned with facilitating laryngeal visualization. no position to the best of our knowledge was applied to aid the introduction of the laryngoscope. the investigators hypothesized that using a special pillow to achieve a modified ramped position (by slight extension of the neck) at the beginning of the laryngoscopy would enhance mouth opening and bring the breasts away from the laryngoscope. after successful introduction of the laryngoscope in the oral cavity, the head could be manually elevated (if required) to achieve sniffing position. the aim of this work is to investigate the feasibility of using the aforementioned modified ramped position for intubation of obese females in comparison to the traditional ramped position.

Eligibility criteria:
inclusion criteria: * female patients * obese (with body mass index above 30 kg per squared meter) * scheduled for surgery under general anesthesia. exclusion criteria: * patients with scars in the face or neck. * edentulous patients. * patients with airway masses.
safety and efficacy trial of olanzapine in outpatients with pathological gambling

Conditions: Pathological Gambling

Summary: the purpose of this research study is to evaluate the efficacy (effectiveness) and safety of olanzapine in treating pathological gambling.


Eligibility criteria:
inclusion criteria: 1. male and female outpatients aged 18- 75 years of age. 2. patients will have problematic gambling behavior of at least 6 months duration that meets the dsm-iv definition of pathological gambling and a south oaks gambling screen score greater than 5. 3. all patients will have a complete medical and psychiatric history, physical examination, laboratories, and ecg before study entry. 4. baseline laboratory values and ecg must be normal, or abnormalities must be clinically insignificant. 5. patients will not have received any psychotropic medication for at least one week prior to the first study visit. exclusion criteria: 1. patients who have any significant and/or unstable gastrointestinal, neurological, endocrine, cardiovascular, pulmonary, renal, hepatic, immunological or hematological disease; organic brain disease; or cancer as determined by history, physical, ecg, and laboratory examination. 2. patients who are pregnant, intending to become pregnant, nursing, at risk for pregnancy, or not practicing medically acceptable birth control. (a blood pregnancy test will be performed at the screening visit). 3. patients who have ever had psychotic symptoms, who have ever met dsm-iv criteria for a manic episode (i.e., have bipolar i disorder), or who have met criteria for dsm-iv psychoactive substance dependence in the past 1 month. 4. patients who meet dsm-iv criteria for antisocial or borderline personality disorder. 5. patients who use any medications which, in the judgment of the investigator, might have psychotropic effects, or interact unfavorably with olanzapine. for example, patients taking diet pills or stimulants will not be enrolled. 6. patients who have taken any psychiatric medication within 7 days prior to the screening assessment. 7. patients who have a history of hypersensitivity to olanzapine. 8. patients who display clinically significant suicidal ideation. 9. patients who have recently (within the past 3 months) begun any type of non-pharmacologic treatment for pathological gambling (including psychotherapy, behavior therapy, group therapy, or family therapy). this does not exclude participation in support groups (e.g., gamblers anonymous.) patients who have been involved in long-standing psychological therapies (e.g., psychotherapy for at least the last 3 months) will be permitted to continue in that therapy provided that no new therapeutic technique or increase in frequency of psychotherapy occurs concurrent with the study. 10. patients who exhibit or suggest that they may display behavior that will not be conducive to the study procedures.
cyclophosphamide as sole graft-versus-host-prophylaxis after allogeneic stem cell transplantation

Conditions: Multiple Myeloma; Non-Hodgkin-Lymphoma; Hodgkin's Disease

Summary: a phase ii clinical study to assess the efficacy of post-transplantation cyclophosphamide as single-agent gvhd prophylaxis after allogeneic hematopoietic stem cell transplantation in patients with multiple myeloma or lymphoma and to describe the influence of the modified immunosuppression concept on relapse rates, minimal residual disease, immune reconstitution and chimerism.


Eligibility criteria:
inclusion criteria: * patients with multiple myeloma, non-hodgkin's lymphoma or hodgkin's disease after allogeneic stem cell transplantation with reduced intensity conditioning * written informed consent * no uncontrolled infections exclusion criteria: * severe organ dysfunction defined as: * cardiac left ventricular ejection fraction (lvef) of less than 35% * diffusing lung capacity (dlco) of less than 40% * total lung capacity (tlc) of less than 40% * forced expiratory volume (fev1) of less than 40% * total bilirubin \>3mg/dl * creatinine-clearance of less than 40 ml/min * pregnancy or breast feeding * participation in other experimental drug trials
dexamethasone versus demedetomidine addition for adductor canal block

Conditions: Postoperative Pain

Summary: single-injection peripheral nerve block (pnb) is commonly used for perioperative analgesia and anesthesia. three approaches for extending the duration of pnb include continuous pnb with catheter-based techniques, novel local anesthetics delivery systems and addition of novel adjuvants to local anesthetics.


Eligibility criteria:
inclusion criteria: * elective operation * asa status i and ii exclusion criteria: * patient refusal * asa status iii and iv * contraindications to local anesthesia
sensory effects of oral opioid treatment in patients with chronic low back pain

Conditions: Low Back Pain

Summary: chronic low back pain (clbp) afflicts up to 50 million u.s. adults and is a primary cause of disability and reduced quality of life. the prescription of opioids for chronic low back pain (clbp) has increased substantially within the past decade in the u.s. as noted by the cdc in their recent guideline (released in march 2016): "opioids are commonly prescribed for pain. an estimated 20% of patients presenting to physician offices with noncancer pain symptoms or pain-related diagnoses (including acute and chronic pain) receive an opioid prescription. interestingly, patients scoring very high on measures of psychological distress tend to be systematically excluded from rcts, even though this subgroup of patients is highly prevalent within the chronic pain population. this study will provide key information on individual differences in the outcomes of opioid treatment, and its findings should facilitate more effective tailoring of analgesic regimens to individual patient characteristic.

changes in pain sensitivity will be examined (i.e., oih) among subgroups of clbp patients prescribed oral opioid therapy. investigators will conduct a moderate-term, double-blind, randomized controlled trial, and use quantitative sensory testing (qst) to evaluate whether changes in pain sensitivity and pain modulation occur as a result of long-term opioid use. investigators hypothesize that increases in pain sensitivity (i.e., oih) and maladaptive changes in endogenous pain modulation (i.e., enhanced temporal summation of pain) will occur as a result of long-term opioid use, but that these changes will be observed predominantly among patients with high levels of negative affect and pain-related catastrophizing.

Eligibility criteria:
inclusion criteria: 1. age 25-65 2. clbp lasting for more than 6 months as the primary complaint 3. typical pain ratings ≥ 4/10 on a visual analogue scale 4. candidate for oral opioid therapy as assessed at the bwh pain management center 5. able to speak and understand english. exclusion criteria: 1. evidence of delirium, dementia, psychosis, or other cognitive impairment preventing completion of study procedures 2. current (i.e., active) substance use disorder (sud) 3. past history of persistent opioid use (i.e., opioid use for more than 6 months) given that this could affect the biological systems of interest in the present study 4. history of myocardial infarction or other serious cardiovascular condition 5. current peripheral neuropathy 6. current pregnancy, or intention to become pregnant during the study 7. current intrathecal pump.
covid-19-associated anxiety of pregnant women for anomalies, stillbirth and preterm labor-2

Conditions: Anxiety State

Summary: capture of anxiety for anomalies, stillbirth and preterm labor of pregnant women during covid-19 pandemia


Eligibility criteria:
inclusion criteria: * consenting ability exclusion criteria: * language barrier * uncompleted questionary
efficacy of higher albendazole and ivermectin doses on wuchereria bancrofti microfilarial clearance in malawi

Conditions: Lymphatic Filariasis

Summary: albendazole and ivermectin are currently used in combination for annual mass treatment of lymphatic filariasis in africa. although the drugs have been donated, the cost of such programmes is very high and has proven to be a major impediment to the success of programmes in many countries with limited financial resources. data from albendazole treatment of other filarial infections and one study comparing single to multi-dose diethycarbamazine/albendazole in lymphatic filariasis suggest that increased dose and/or frequency of albendazole dosing may be more effective in clearing microfilariae. it is essential to determine whether such higher doses are indeed beneficial since this could have far-reaching effects on the conduct and management of the main mass treatment programmes and also in the management of programmes as they near elimination.

the proposed study will enrol up to 120 volunteers with microfilaremic wuchereria bancrofti infection who would be randomized to receive standard annual treatment (albendazole 400 mg + ivermectin 200 mcg/kg), annual treatment with an increased dose of albendazole (albendazole 800 mg + ivermectin 200400 mcg/kg) or semi-annual treatment with a standard (albendazole 400 mg + ivermectin 200 mcg/kg), or an increased albendazole dose (albendazole 800 mg + ivermectin 200 400 mcg/kg). microfilarial levels, as well as measures of adult worm burden (circulating antigen) will be followed every six months for two years to determine whether the higher doses, or more frequent regimens are more effective. the data obtained would be used, in combination with the data from other similar studies being conducted in mali and in india to advise the global programme for the elimination of lymphatic filariasis (gpelf) on improved methods of treatment both for mass treatment and for the management of problem areas within the global programme.

Eligibility criteria:
inclusion criteria: * understand and sign informed consent * willing to undergo night blood sampling every 6 months for 2 years * age 18 to 55 years * haemoglobin of equal or above 9g/dl * microfilarial level of equal or above 80mg/dl exclusion criteria: * non- consenting * pregnancy or lactation * treatment with albendazole or ivermectin within the previous 6 months * known allergy to the study drugs

Keywords: lymphatic filariasis microfilaria albendazole ivermectin human immunodeficiency
assessing the utility of plasma cthpvdna for anal cancer screening

Conditions: Anal Dysplasia

Summary: the study is to test a liquid biopsy assay for screening and classifying anal dysplasia from blood.

anal squamous cell carcinoma, despite being considered as a rare cancer, has seen a steady rise in incidence over the past three decades. recent evidence from the anal cancer-hsil outcomes research (anchor) study demonstrated benefits of treating anal high-grade squamous intraepithelial lesion (hsil), highlighting the importance of screening anal cancers and high-grade precancers. current anal cancer screening starts with hpv testing and/or cytology for primary screening, followed by high-resolution anoscopy (hra) with biopsy for confirmatory diagnosis. however, the poor specificity of hpv testing and the extremely limited capacity of hra urges the development of new screening approaches for identifying anal high-grade precancers and cancers. blood circulating tumor hpv dna (cthpvdna) is an emerging non-invasive biomarker for screening and treatment monitoring of hpv-associated cancers, but its significance in anal cases remains underexplored. here the investigators use an ultrasensitive hpv whole genome sequencing assay to test the hypothesis that anal precancers are detectable in the blood.

Eligibility criteria:
inclusion criteria: * past or current anal hpv-positive population undergone anal dysplasia screening. * control patients from the general population. exclusion criteria: * not meeting inclusion criteria.

Keywords: hpv liquid biopsy anal cancer anal intraepithelial neoplasia early cancer detection hpv-deepseek ngs
comorbid insomnia and sleep disordered breathing in patients undergoing cardiac rehabilitation

Conditions: Coronary Artery Disease; Sleep Disorder; Breathing-Related; Sleep Disorder; Insomnia Type

Summary: the purpose of this research is to determine how frequently sleep disorders such as sleep disordered breathing and insomnia occur in patients with coronary artery disease enrolled in cardiac rehabilitation. by reviewing results of a variety of tests, we also hope to learn more about the cardiovascular effects on people who may have these conditions.

patients referred to the mayo clinic rochester cr and meeting eligibility criteria (see subjects section below) will be recruited and consented. prior to beginning cr, enrolled patients will undergo baseline sleep and cv assessment at the clinical research and trials unit (crtu). home-based sleep monitoring will take place. patients will also complete additional cardiometabolic and behavioral evaluation as part of the standard cr clinical care. following completion of the 12-week cr program, a post-cr assessment may be conducted, including the same set of tests/procedures. all patients will be followed up for at least 6-months following enrollment to monitor cardiac recurrence, hospitalization and death.

Eligibility criteria:
inclusion criteria: * patients will be \>18 years old * referred to cr following admitted to the hospital with a documented diagnosis of acute coronary syndrome * referred to cr following admission to the hospital with a documented diagnosis of st- elevation myocardial infarction (stemi), * referred to cr following admission to the hospital with a documented diagnosis of non- stemi * referred to cr following admission to the hospital with a documented diagnosis of unstable angina * referred to cr following admission to the hospital with a documented diagnosis of post coronary artery bypass surgery * referred to cr following admission to the hospital after percutaneous coronary intervention (with or without stent placement). exclusion criteria: * heart failure with reduced ejection fraction * peripheral artery disease * valve or pericardial surgery * heart transplantation * patients unable to provide informed consent * patients unable to speak and read english * night shift workers * pregnant women * those who will only attend full home-based cr.
a novel noninvasive thermoregulatory device for postural tachycardia syndrome

Conditions: Postural Tachycardia Syndrome

Summary: the investigators hope to learn the feasibility and preliminary efficacy of the embr device for improving thermal comfort in individuals with pots and impaired thermoregulation. feasibility will be assessed via usage of the embr device and participant feedback. preliminary efficacy measures will include temperature-related symptoms and temperature- related quality of life in individuals with pots and impaired thermoregulation.


Eligibility criteria:
inclusion criteria: * diagnosis of pots * participant self-report of heat or cold intolerance * willingness to wear the embr device for 3 weeks, charging the device daily, and * have a working smartphone (iphone 6 or greater; or android 8.0 or greater * comfortable downloading and using the companion app on their phone * able to provide informed written consent * able to complete written questionnaires exclusion criteria: * prior or current use of the study device * hypohidrosis, hyperhidrosis, or anhidrosis, as determined by sudomotor testing; peripheral neuropathy; perimenopausal, menopausal, postmenopausal state; temperature intolerance due to other medical disorders (i.e. malignancy, systemic autoimmune disease) * medications known to affect sweat function * non-english speaking

Keywords: thermoregulation
pre-approval access to rilpivirine long acting (rpv la) injectable suspension for the treatment of a participant with human immunodeficiency virus (hiv)-1 infection

Conditions: HIV

Summary: the main purpose of this pre-approval access program (paap) is to provide rilpivirine long acting (rpv la) injectable suspension for the treatment of human immunodeficiency virus (hiv)-1 infection as single patient request to individuals who have no available treatment alternatives and/or limited treatment options (for example, who are unable to participate in the phase iii clinical studies or do not qualify). rpv la can only be provided if participants are also eligible for cabotegravir long acting injections.


Eligibility criteria:

Keywords: rilpivirine long acting rilpivirine injection hiv rilpivirine expanded access rilpivirine single patient request